12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Farletuzumab: Preliminary Phase III data

Preliminary data from the double-blind, international Phase III Study FAR 131 (MORAb-003-004) trial in 1,100 patients with platinum-sensitive epithelial ovarian cancer in first relapse showed that IV farletuzumab plus carboplatin and taxane chemotherapy missed the primary endpoint of improving PFS vs. placebo plus carboplatin and taxane chemotherapy. Eisai also said a post...

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >